BETA
Your AI-Trained Oncology Knowledge Connection!
Efficacy and Safety of Bruton Tyrosine Kinase Inhibitors in B-Cell Malignancies
B-cell malignancies are a heterogeneous subset of non-Hodgkin lymphomas in which treatment has remained essentially unchanged for the past 3 decades.
BTK Inhibitors: Real-World Insights on Patient Management and Therapy Selection
Nathan H. Fowler, MD, discusses the use of BTK inhibitors in B-cell malignancies.
The Changing Treatment Landscape in MCL and CLL: A Review of Standards of Care
Among the many new developments in B-cell lymphoma in recent years, the inhibition of Bruton tyrosine kinase represents a particularly notable achievement.
T-DM1 Plus Palbociclib Displays Activity in HER2+ Metastatic Breast Cancer
EL1SSAR Data Shed Light on Leveraging Atezolizumab Plus Nab-Paclitaxel in PD-L1+ TNBC
Pretreatment ctDNA Status Is Associated With Distant Recurrent-Free Survival in Early Breast Cancer
Zanidatamab/Chemotherapy Yields Responses and Is Safe in HER2-Expressing Metastatic Breast Cancer
%20(1).jpg?fit=crop&auto=format)
